Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sipai Health Technology Co's annualized net income for the quarter that ended in Dec. 2025 was €-12.7 Mil. Sipai Health Technology Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €113.7 Mil. Therefore, Sipai Health Technology Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -11.15%.
The historical rank and industry rank for Sipai Health Technology Co's Return-on-Tangible-Equity or its related term are showing as below:
FRA:AX1'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -23.64 Med: -15.71 Max: -12.09
Current: -12.3
During the past 7 years, Sipai Health Technology Co's highest Return-on-Tangible-Equity was -12.09%. The lowest was -23.64%. And the median was -15.71%.
FRA:AX1's Return-on-Tangible-Equity is ranked worse than 85.84% of 113
companies
in the Medical Distribution industry
Industry Median: 8.78
vs FRA:AX1: -12.30
Sipai Health Technology Co (FRA:AX1) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sipai Health Technology Co Return-on-Tangible-Equity Related Terms
Sipai Health Technology Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sipai Health Technology Co Return-on-Tangible-Equity Chart
FRA:AX1 vs MCK, COR, CAH: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Sipai Health Technology Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sipai Health Technology Co Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sipai Health Technology Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sipai Health Technology Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -11.15% mean?
Sipai Health Technology Co (FRA:AX1) has a Return-on-Tangible-Equity of -11.15% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sipai Health Technology Co and its competitors. According to the industry distribution chart, Sipai Health Technology Co ranks #97 out of 113 companies in the Medical Distribution industry, placing it in the top 85.8%.
Is Sipai Health Technology Co's Return-on-Tangible-Equity too high?
Sipai Health Technology Co's current Return-on-Tangible-Equity is -11.15%. Based on the distribution chart, Sipai Health Technology Co ranks #97 out of 113 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sipai Health Technology Co has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Sipai Health Technology Co's Return-on-Tangible-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sipai Health Technology Co ranks #97 out of 113 companies for Return-on-Tangible-Equity. This places Sipai Health Technology Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.78, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sipai Health Technology Co and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sipai Health Technology Co's current Return-on-Tangible-Equity is -11.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sipai Health Technology Co stock overvalued right now?
Sipai Health Technology Co (FRA:AX1) has a current Return-on-Tangible-Equity of -11.15%. The stock's GF Value™ is €0.22, compared to a current price of €0.14 — trading 36.8% below its estimated fair value. The current Return-on-Tangible-Equity is -11.15%. Sipai Health Technology Co's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sipai Health Technology Co (FRA:AX1), the current Return-on-Tangible-Equity is -11.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sipai Health Technology Co (FRA:AX1) Overvalued in 2026?
Based on GuruFocus' analysis, Sipai Health Technology Co stock appears to be undervalued.
The current stock price of €0.14 is trading 36.8% below its estimated GF Value™ of €0.22.
Key valuation signals for FRA:AX1:
Return-on-Tangible-Equity: -11.15%
GF Value™: €0.22 vs. price of €0.14 (36.8% below fair value)
No single metric tells the full story. See the FRA:AX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sipai Health Technology Co Ltd is a medical technology and health management company in China. The company has three reportable operating segments: Specialty Pharmacy Business - engaged in the operation and distribution of specialty pharmacy stores and pharmaceutical products; Physician Research Assistance Business - offering pharmaceutical companies and other clinical trial institutions site management organization services; Commercial Insurance Services Business - rendering insurance brokerage services to insurance companies and health management services to insurance carriers and enterprise clients. The company generates key revenue from the Specialty Pharmacy Business. Almost all of the company's revenues were derived from operations in the PRC.
64GF Score
Get the complete analysis for FRA:AX1
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AX1 has been successfully added to your 
